What is the current stock price of Ovid Therapeutics Inc. (OVID)?

As of the latest market data, Ovid Therapeutics Inc. (OVID) is trading at $2.75. The stock has seen a loss of -4.51% today.

Does Ovid Therapeutics Inc. (OVID) pay a dividend?

Based on current data, Ovid Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Ovid Therapeutics Inc.?

The current market capitalization of Ovid Therapeutics Inc. (OVID) is approximately unavailable.

OVID

Ovid Therapeutics Inc.·Healthcare

2.75

4.514%(−0.13)

Market Closed

3.00

9.091%(+0.25)

After Hours

Last Updated: — ET

52W L: $0.2652W H: $3.10

OVID NEWS

globenewswire.com

2d ago

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

NEW YORK, April 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing small molecule medicines for brain disorders with significant unmet need, today announced the Company will host a KCC2 Deep Dive R&D event highlighting its first-in-class KCC2 portfolio on Tuesday, April 14, 2026, at 9:30 am ET in New York, NY, which will also be webcast simultaneously. During the event independent expert clinicians and translational experts as well as Ovid's President and Chief Executive Officer Meg Alexander, will discuss the Company's proprietary portfolio of potential first-in-class direct activators of KCC2, including pharmacodynamic data, translational and clinical development strategy, and the potential market opportunity.

defenseworld.net

Mar 26

Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Ovid Therapeutics (NASDAQ: OVID - Get Free Report) have received an average rating of "Buy" from the nine research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to

seekingalpha.com

Mar 20

Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding

Ovid Therapeutics advances OV329, a GABA-AT inhibitor, into Phase 2 for drug-resistant adult focal onset seizures after soticlestat's failure. Recent Phase 1 data show OV329 lacks the eye toxicity seen with vigabatrin, supporting its differentiated safety profile. Management secured $60M PIPE financing, extending the cash runway into 2029, but a $385.7M modeled funding gap implies 11% annual dilution over six years.

seekingalpha.com

Mar 18

Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript

fool.com

Mar 18

Here's Why Ovid Therapeutics Stock Popped Higher Today

OV329 may be safer and more potent than existing treatments. A $60M private placement will fund further development.

benzinga.com

Mar 18

Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally

Ovid Therapeutics reported favorable topline safety and tolerability findings from a 7 mg dose cohort of OV329 for drug-resistant epilepsies.

Company Profile

Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-05-05

Beta

-0.03

Websitewww.ovidrx.com↗